Newsletter | October 4, 2021

10.04.21 -- Strategies To Optimize Cell And Gene Therapy Manufacturing

Scaling Up Gene Therapy Manufacturing With Single-Use Technology

Key considerations need to be made when selecting a single-use technology supplier to ensure you choose one that best meets your needs as well as allows you to scale to your target operation sizes.

Improved Control Of Activation And Expansion Of Tregs For Use In Cell Therapy Applications

CTS Dynabeads CD3/CD28 is a platform technology applied for ex vivo manufacture of polyclonal T cells for use in various adoptive cell therapies. Here, we present a new bead, CTS Dynabeads Treg Xpander, which is a modification of this platform to specifically activate and expand regulatory T cells (Tregs).

Your Gene Therapy Roadmap From Production To Commercialization

Advancement in gene therapies offer great promise to treat life-threatening diseases. See how these end-to-end gene therapy solutions can support your viral vector workflow on your journey from production to commercialization.

Upcoming Webinar